Roche Holding AG has agreed to buy U.S. biotech company InterMune Inc for $8.3 billion in cash, helping the world's leading maker of cancer drugs expand into the treatment of rare or incurable diseases.
IF THE RESULTS COME CLOSE TO THE 2 phase 1 trial results then the FDA might grant compassionate approval. the stock would explode if that happened. the latest interim results show ahigh percentage of success. Some of the people in the trial have had a complete response. That is almost a miracle considering they had tried everything and nothing worked until now. I expect some great PR soon.
It would be great to get some good news and get some traction for this stock. Since January, 2013, any possibly good news has been ignored as measured by the stock price.
If results continue to be 60% or better than SOC, that would be wildly positive.
Thermodox has proven to be safe. Heat sensitive liposomes pose no problem to the body and doxorubicin has been in use for decades.
Considering the aforementioned, I believe the FDA will prompt Celsion to file for approval and make the treatment available as the new SOC for recurrent chest wall cancer.
The market should take notice and the stock price should jump to $20 - $50 or more per share.
Next year, when the DMC checks results from Optima I would not be surprised to hear positive news and another surge in share price.
Estimated Enrollment: 20
Study Start Date: February 2013
Estimated Study Completion Date: November 2014
Estimated Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
and 97% below the prior reverse split price ?
1:15 and 1:4-1/2
is this a visionary managment team who cares about you, or about themselves?
The history of CLSN combined with recent financials makes the future obvious.
History of repeated fundraisers - D I L U T I O N
History of reverse splits - 1:15 and 1:4.5
History of failures and overcompensation
With couple of exceptions, history of small open market insiders purchases
Based on burn rate and rapidly reducing net cash (current assets less debts), CLSN never waits until the last hour to increase working capital. Count on more fundraisers coming.
We like the acquisition. Celsion will gain a sound research arm to complement its own clinical development expertise. The deal will also expand the R&D pipeline with drugs that may be used with its ThermoDox one day. We will update our financial model fully once the deal is completed. Meanwhile, we are maintaining our BUY recommendation and $8.00 price target.
Sentiment: Strong Buy
Meanwhile, it looks like someone is unloading a bunch of shares today. Down big on big volume. Not what you want to see.
These are ridiculously low token buys of $12,000. Means nothing. If you are making $700k per year, you want to show your support of the company, but $12k means nothing. They can keep raising money for the next 20 years and keep their big salaries and make token $12k buys.